 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Tuesday, November 07, 2006
"Critical Outcome Technologies Inc. announces the final selection of its library of orally available lead compounds for the treatment of acute MS" PRESS RELEASE
"
LONDON, Ontario--(CCNMatthews - Nov. 7, 2006) - Critical Outcome Technologies
Inc. (TSX-V: COT), a computational drug discovery and pre-clinical drug development
company, has completed the discovery, optimization and final selection of its library of
lead compounds for the oral treatment of acute Multiple Sclerosis.
The compounds have
been engineered to be orally available, have low toxicity, cross the blood brain barrier
and selectively inhibit Vascular Endothelial Growth Factor (VEGF-R) and Platelet
Derived Growth Factor (PDGF-R) receptor kinases.
The first four lead candidates are now being synthesized at Dalton Pharma Services,
Toronto, Canada, prior to undergoing efficacy and toxicity testing in a validated animal
model of acute allergic encephalitis. Critical Outcome Technologies Inc. (COTI) expects
the synthesis to be completed by the end of January 2007..."
"
LONDON, Ontario--(CCNMatthews - Nov. 7, 2006) - Critical Outcome Technologies
Inc. (TSX-V: COT), a computational drug discovery and pre-clinical drug development
company, has completed the discovery, optimization and final selection of its library of
lead compounds for the oral treatment of acute Multiple Sclerosis.
The compounds have
been engineered to be orally available, have low toxicity, cross the blood brain barrier
and selectively inhibit Vascular Endothelial Growth Factor (VEGF-R) and Platelet
Derived Growth Factor (PDGF-R) receptor kinases.
The first four lead candidates are now being synthesized at Dalton Pharma Services,
Toronto, Canada, prior to undergoing efficacy and toxicity testing in a validated animal
model of acute allergic encephalitis. Critical Outcome Technologies Inc. (COTI) expects
the synthesis to be completed by the end of January 2007..."